MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
ENDRA Life Sciences Operating Income 2011-2026 | NDRA
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.76 M | -10.8 M | -10.5 M | -13.2 M | -11.5 M | -11.5 M | -10.8 M | -9.02 M | -4.63 M | -1.79 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.79 M | -13.2 M | -8.95 M |
Quarterly Operating Income ENDRA Life Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.37 M | -1.3 M | -1.47 M | - | -1.51 M | -2.23 M | -2.78 M | - | -3.13 M | -2.99 M | -2.94 M | - | -3.42 M | -3.57 M | -2.86 M | - | -2.65 M | -3.2 M | -2.58 M | - | -3.26 M | -2.89 M | -3.1 M | - | -2.64 M | -2.33 M | -2.75 M | - | -2.36 M | -1.82 M | -2.84 M | - | -911 K | -1.06 M | -361 K | - | -605 K | -494 K | -373 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -361 K | -3.57 M | -2.19 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioNano Genomics
BNGO
|
-33.3 M | $ 1.14 | 0.44 % | $ 6.21 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.07 | 1.39 % | $ 173 M |  China |
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.35 B | $ 115.09 | 0.03 % | $ 35 B | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 2.25 | -2.17 % | $ 9.95 M | USA |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 16.32 | 1.65 % | $ 870 M | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 498.22 | 0.95 % | $ 14.4 B | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.45 | 2.3 % | $ 412 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 7.87 | 2.34 % | $ 1.01 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.4 | 2.19 % | $ 1.86 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 23.05 | -0.35 % | $ 640 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 6.62 | -0.9 % | $ 276 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 176.51 | 0.49 % | $ 8.75 B | USA |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 52.58 | -0.1 % | $ 2.67 B | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 190.99 | 0.73 % | $ 136 B | USA |
 |
Neuronetics
STIM
|
-31.4 M | $ 1.37 | 1.11 % | $ 90.4 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 122.69 | 1.46 % | $ 19.5 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 14.96 | 3.67 % | $ 452 M | USA |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 500.25 | 0.83 % | $ 189 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.62 M | $ 0.69 | -3.28 % | $ 61.9 M |  Irlanda |
 |
Guardant Health
GH
|
-437 M | $ 79.27 | 0.85 % | $ 9.94 B | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B |  Niderland |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 48.44 | 1.11 % | $ 2.9 B | USA |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.73 | 1.49 % | $ 88.6 K | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.1 | -2.1 % | $ 4.82 M | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 28.26 | -0.18 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 107.45 | 0.59 % | $ 8.86 B | Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 261.12 | 0.07 % | $ 21.7 B | USA |
 |
Natera
NTRA
|
-541 M | $ 197.55 | 2.34 % | $ 19.4 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 118.08 | 0.8 % | $ 5.52 B | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 80.41 | -0.23 % | $ 5.43 B | USA |
 |
Waters Corporation
WAT
|
271 M | $ 318.26 | -0.54 % | $ 19 B | USA |